- |||||||||| Journal: Novel AIP mutation in exon 6 causing acromegaly in a German family. (Pubmed Central) - Jul 17, 2023
Apart from reporting a novel AIP mutation, this study does not only highlight the different clinical and histological features of the AIP mutated growth hormone producing pituitary neuroendocrine tumors but also confirms the poor responsiveness of dopamine agonists in AIP mutated acromegaly. Furthermore, it highlights the increased mortality risk of comorbidities typically associated with acromegaly.
- |||||||||| Signifor (pasireotide) / Recordati
Journal: Identification of a Novel SSTR3 Full Agonist for the Treatment of Nonfunctioning Pituitary Adenomas. (Pubmed Central) - Jul 14, 2023
Synthetic therapeutic agonists showing selectivity for SSTR2 (Octreotide) or for SSTR2 and SSTR5 (Pasireotide) have been approved for the treatment of patients with acromegaly and Cushing's syndrome, as their pituitary tumors highly express SSTR2 or SSTR2/SSTR5, respectively...Furthermore, ITF2984 displays antitumor activity that is dependent on SSTR3 expression levels in the MENX (homozygous mutant) NFPA rat model, which closely recapitulates human disease. Therefore, ITF2984 may represent a novel therapeutic option for patients affected by NFPA.
- |||||||||| Journal: Plurihormonal Pituitary Neuroendocrine Tumours - A Single Centre Experience. (Pubmed Central) - Jul 13, 2023
Retrospective studies related to newly defined plurihormonal PitNETs with a reassessment of diagnoses are necessary due to their rarity and ambition to investigate their origin and biological behaviour. The fact that the majority of plurihormonal PitNETs are clinically presented with acromegaly and show simultaneous positivity to PIT1 and SF1 transcription factors deserve special attention and need for further research in larger cohorts of these exceptional tumours.
- |||||||||| Review, Journal: Pituitary tumors and the risk of other malignancies: is the relationship coincidental or causal? (Pubmed Central) - Jul 12, 2023
Besides the inherited trophic mechanisms (shared underlying genetic variants), the potential influence of shared complex epigenetic influences (environmental and behavioral factors - obesity, smoking, alcohol intake and insulin resistance) is discussed. Further studies are needed to better understand if patients with pituitary adenomas are at increased risk for cancer.
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
Review, Journal: Refractory somatotroph adenomas. (Pubmed Central) - Jul 12, 2023
Some tumors have a more aggressive behavior and are refractory to standard therapy. In this review, we summarize the phenotype of these tumors and the current options for their management.
- |||||||||| Somavert (pegvisomant) / Pfizer
Trial completion: PegvisOMant and the Immune SystEm (PROMISE) (clinicaltrials.gov) - Jul 6, 2023
P=N/A, N=62, Completed,
Therefore, novel formulas or combinations of currently marketed medications and emergent phytochemicals will provide new possibilities for these instances. Active, not recruiting --> Completed
- |||||||||| lactulose / Generic mfg.
Review, Journal: Epidemiology of small intestinal bacterial overgrowth. (Pubmed Central) - Jul 4, 2023
In a number of diseases, including cirrhosis, MAFLD, diabetes, and pancreatitis, an association was found between disease severity and the presence of SIBO. Further work on the effect of SIBO eradication on the condition and prognosis of patients with various diseases is required.
- |||||||||| Journal: Germline loss-of-function PAM variants are enriched in subjects with pituitary hypersecretion. (Pubmed Central) - Jul 4, 2023
By interrogating 200,000 exomes from the UK Biobank, we confirmed a significant association of the PAM gene and rare PAM SNVs with diagnoses linked to pituitary gland hyperfunction. The identification of PAM as a candidate gene associated with pituitary hypersecretion opens the possibility of developing novel therapeutics based on altering PAM function.
- |||||||||| Review, Journal: Role of Estrogen and Estrogen Receptor in GH-Secreting Adenomas. (Pubmed Central) - Jul 2, 2023
In recent years, the role of estrogens and Selective Estrogens Receptor Modulators (SERMs) in acromegaly treatment has been re-evaluated, especially considering poor control of the disease under first- and second-line medical treatment. In this review, we analyze the state of the art concerning the impact of estrogen and SERMs on the GH/IGF1 axis, focusing on molecular pathways and the possible implications for acromegaly treatment.
- |||||||||| Journal: Endoscopic endonasal approach for acromegaly: surgical outcomes using 2018 consensus criteria for remission. (Pubmed Central) - Jun 30, 2023
The endoscopic endonasal surgery promotes high short-term and two-year remission rates in acromegaly; the tumor's volumetry and the T2 hypersignal were statistically significant prognostic factors in non-remission - the complications presented at similar rates in comparison to the literature. In invasive GH-secreting tumors, we should offer these patients a multi-disciplinary approach to improve acromegalic patients' remission rates.
- |||||||||| Somavert (pegvisomant) / Pfizer
Preclinical, Journal: Excessive growth hormone promotes joint degeneration and chondrocyte metabolic dysfunction in mice. (Pubmed Central) - Jun 29, 2023
In invasive GH-secreting tumors, we should offer these patients a multi-disciplinary approach to improve acromegalic patients' remission rates. This study showed that an excessive amount of GH promotes joint degeneration in mice, which was associated with chondrocyte metabolic dysfunction and hypertrophic changes, whereas antagonizing GH action through a GHa protects mice from OA development.
- |||||||||| Oclaiz (octreotide subcutaneous depot) / Camurus
Enrollment closed, Trial completion date, Trial primary completion date: A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly (clinicaltrials.gov) - Jun 22, 2023
P3, N=135, Active, not recruiting,
According to this study, a pituitary gland with a height > 4 mm or a P:B ratio > 0.49 mm should be considered enlarged. Recruiting --> Active, not recruiting | Trial completion date: Oct 2023 --> Jun 2025 | Trial primary completion date: Sep 2023 --> Jun 2025
- |||||||||| Review, Journal: Bone quality in endocrine diseases: determinants and clinical relevance. (Pubmed Central) - Jun 14, 2023
These results indicate that epigenetic regulation affects GIPR expression in GH-PAs, even though this possibly represents only a part of a much more complex regulatory mechanism. Assessment of skeletal fragility in endocrine diseases might take advantage from the use of techniques to detect perturbation in bone architecture with the aim of best identifying patients at high risk of fractures.
- |||||||||| paltusotine (CRN00808) / Crinetics
Trial completion date, Trial primary completion date: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) (clinicaltrials.gov) - Jun 13, 2023
P3, N=98, Recruiting,
Assessment of skeletal fragility in endocrine diseases might take advantage from the use of techniques to detect perturbation in bone architecture with the aim of best identifying patients at high risk of fractures. Trial completion date: Aug 2025 --> Jan 2026 | Trial primary completion date: Aug 2023 --> Feb 2024
- |||||||||| Review, Journal: Molecular Imaging of Pituitary Tumors. (Pubmed Central) - Jun 12, 2023
In addition, novel approaches to distinguish adenomatous tissue from normal gland (eg through comparison of images obtained with different radiotracers) and increase confidence that a suspected abnormal focus is indeed pathological (eg through subtraction imaging) have been proposed. It is likely therefore that molecular imaging will continue to find increasing application in the management of pituitary tumors just as it already does in other endocrine disorders.
- |||||||||| Retrospective data, Journal: IGF-1 is positively associated with BMI in patients with acromegaly. (Pubmed Central) - Jun 9, 2023
In contrast to individuals without acromegaly, BMI is significantly and positively associated with IGF-1 in acromegaly across the weight spectrum. Future studies are needed to determine if obese patients with acromegaly experience more significant symptoms related to their disease, or if patients with a low BMI may require different diagnostic criteria.
- |||||||||| Journal: Using 2-dimensional hand photographs to predict postoperative biochemical remission in acromegaly patients: a transfer learning approach. (Pubmed Central) - Jun 7, 2023
As expected, the MobileNetv2-based transfer learning algorithm was shown to predict biochemical remission with statistical accuracies of 0.96 and 0.76 in the training cohort (n=803) and validation cohort (n=200), respectively, and the loss function value was 0.82. Our findings demonstrate the potential of the MobileNetv2-based transfer learning algorithm in predicting biochemical remission for postoperative patients who are at home or live far away from a pituitary or neuroendocrinological treatment center.
- |||||||||| cimdelirsen (IONIS-GHR-LRx) / Ionis
Trial completion, Trial completion date, Trial primary completion date, Monotherapy: A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly (clinicaltrials.gov) - Jun 6, 2023
P2, N=34, Completed,
The purpose of this report is to raise awareness of this subtype and encourage a comprehensive immunohistochemical workup for accurate classification of PitNETs. Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> May 2023 | Trial primary completion date: Aug 2023 --> Jul 2022
- |||||||||| Somavert (pegvisomant) / Pfizer, Signifor (pasireotide) / Recordati
Review, Journal: Secondary diabetes mellitus in acromegaly. (Pubmed Central) - Jun 5, 2023
In turn, metformin, pioglitazone and sodium-glucose transporters 2 inhibitors might be disease-modifying by counteracting hyperinsulinemia or acting pleiotropically. Large, prospective cohort studies are needed to validate the above notions and define optimal DM management in acromegaly.
- |||||||||| Enrollment open, Trial initiation date: Acromegaly: Balance, Falls and Fracture Risk (clinicaltrials.gov) - Jun 2, 2023
P=N/A, N=60, Recruiting,
This registry study provides epidemiological data on patients with acromegaly in Malaysia and serves as an initial step for further population-based studies. Not yet recruiting --> Recruiting | Initiation date: Mar 2023 --> Jun 2023
- |||||||||| Journal: Growth Hormone Excess: Implications and Management. (Pubmed Central) - Jun 1, 2023
All human research articles and review articles published in English were considered for the review. In this review, we describe the clinical implications and management of patients with acromegaly, consisting of scientific improvements underlying the developing understanding of pathogenesis and diagnosis, associated comorbidities and mortality rate with the disease, and major improvements in the treatment of the disease, along with novel strategies including quality of life and patient-reported outcomes.
- |||||||||| octreotide 3-month extended release (Debio 4126) / Debiopharm
Trial completion date, Trial primary completion date: OXTEND-01: A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) (clinicaltrials.gov) - May 31, 2023
P1b, N=30, Recruiting,
In this review, we describe the clinical implications and management of patients with acromegaly, consisting of scientific improvements underlying the developing understanding of pathogenesis and diagnosis, associated comorbidities and mortality rate with the disease, and major improvements in the treatment of the disease, along with novel strategies including quality of life and patient-reported outcomes. Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Jan 2025 --> May 2025
- |||||||||| temozolomide / Generic mfg.
Review, Journal: Multidisciplinary management of difficult/aggressive growth-hormone pituitary neuro-endocrine tumors. (Pubmed Central) - May 23, 2023
A multidisciplinary approach is particularly useful in difficult/aggressive acromegaly to schedule multimodal treatment, which includes radiation therapy, chemotherapy with temozolomide and other, recent emerging treatments. Herein, we describe the role of the different members of the multidisciplinary team according to our personal experience; a flow-chart for the therapeutic approach of difficult/aggressive acromegaly patients is proposed.
- |||||||||| Review, Journal: Octreotide and Octreotide-derived delivery systems. (Pubmed Central) - May 22, 2023
Meanwhile, variety of Octreotide-derived delivery strategies have been proposed and explored for tumor targeted therapeutics or diagnostics in preclinical or clinical settings. In this review, we especially focus on the preclinical development and applications of Octreotide-derived drug delivery systems, diagnostic nanosystems, therapeutic nanosystems and multifunctional nanosystems, we also briefly discuss challenges and prospects of these Octreotide-derived delivery systems.
|
